City Therapeutic Doses First Patient In Its Clinical Study Of CITY-RBP4 To Treat Stargardt Disease Type 1

City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, today announced that the first participant has been dosed in the Phase 1 clinical trial of CITY-RBP4, an investigational RNAi therapeutic candidate for the treatment of Stargardt disease type 1 (Stargardt disease). CITY-RBP4 is designed to silence expression of retinol-binding protein 4 (RBP4) to reduce the delivery of vitamin A to the eye and potentially slow the progression of retinal damage and vision loss associated with Stargardt disease. City expects to report initial data from the Phase 1 trial in mid-2027.